TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.-Reference-Cited by-同舟云学术

TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.

Published:2024-01 Issue: Volume:253 Page:155008
ISSN:0344-0338
Container-title:Pathology - Research and Practice
language:en
Short-container-title:Pathology - Research and Practice

Author:

Mollica Veronica^ORCID,Tassinari Elisa,Santoni Matteo,Marchese Paola Valeria,Giunchi Francesca,Maloberti Thais,Tateo Valentina,Ricci Costantino,Rosellini Matteo,Marchetti Andrea,Fiorentino Michelangelo,Biase Dario De,Massari Francesco

Funder

Ministero della Salute

Publisher

Elsevier BV

Subject

Cell Biology,Pathology and Forensic Medicine

Reference27 articles.

1. Cancer statistics, 2023;Siegel;CA Cancer J. Clin.,2023

2. Treatment options for metastatic urothelial carcinoma after first-line chemotherapy;Tassinari;Cancer Manag. Res.,2022

3. Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after ≥2 years of follow-up;Powles;J. Clin. Oncol.,2023

4. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up;Fradet;Ann. Oncol.,2019

5. Enfortumab vedotin in previously treated advanced urothelial carcinoma;Powles;N. Engl. J. Med.,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Telomerase Reverse Transcriptase-Promoter Mutation in Young Patients with Bladder Tumors;Current Issues in Molecular Biology;2024-03-23